Skip to content

ACADIA Pharmaceuticals

US · ACAD #2404 by market cap Listed 1970
17.11 -0.48 -2.73%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $23 to $38
    Market Newswire · 2026/11/6
  • Company notice
    AMA Group Ltd: GUD: Investor Presentation - ACAD Division from AMA Group
    N/A · 2020/11/19
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX)
    TipRanks · 2026/9/25
  • Rating change
    RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $36
    Market Newswire · 2026/10/8
  • BMO Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $34
    Market Newswire · 2026/11/11
  • Company notice
    GUD Holdings Ltd: AMA: Completion of ACAD sale and operating update
    N/A · 2020/12/31
  • Rating change
    A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $31 to $36
    Market Newswire · 2026/9/26
  • Company notice
    AMA Group Ltd: Completion of ACAD sale and operating update
    N/A · 2020/12/31
  • Rating change
    BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $31
    Market Newswire · 2026/10/9
  • Rating change
    Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/10/19
  • Rating change
    Analysts' Top Healthcare Picks: Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD)
    TipRanks · 2026/9/25
  • Company notice
    GUD Holdings Ltd: GUD completes acquisition of ACAD Businesses
    N/A · 2020/12/31
  • BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $31
    Market Newswire · 2026/11/11
  • Rating change
    RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38
    Market Newswire · 2026/11/5
  • CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38
    Market Newswire · 2026/11/6
  • Rating change
    UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $23
    Market Newswire · 2026/10/14
  • Rating change
    UBS Downgrades ACADIA Pharmaceuticals(ACAD.US) to Hold Rating, Cuts Target Price to $23
    Market Newswire · 2026/10/13
  • Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Cuts Target Price to $24
    Market Newswire · 2026/11/13
  • Company notice
    GUD Holdings Ltd: Investor Presentation - ACAD Division from AMA Group
    N/A · 2020/11/19
  • Rating change
    RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $37
    Market Newswire · 2026/10/6
  • Rating change
    CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/9/3
  • Rating change
    Deutsche Bank Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38
    Market Newswire · 2026/8/25
  • BMO Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $34
    Market Newswire · 2026/10/13
  • Rating change
    A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $40
    Market Newswire · 2026/8/25
  • Rating change
    BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $36
    Market Newswire · 2026/8/18

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ACADIA Pharmaceuticals discussion 0 comments

Add a comment